NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered Tirzepatide from Reta-Peptide? Mail in a sample (US only) and let us test it.

Test my supply
+19 more ↓
85%
Finnrick rating
#14 of 281 Tirzepatide vendors
34 of 39 classifiable tests passed
customers 4.9★ (23)
methodology · Purity focus
Finnrick analysis · Tirzepatide

Reta-Peptide tirzepatide is strong but uneven: a recent 92.9% purity failure and earlier -58%/+38% fill misses are the main drag. Two later Nov tests had passing identity/fill and 99.9% purity with batch IDs; rebound is the key pattern.

methodology →
vendor intelligence report
Vendor Intelligence Report: Reta-Peptide

Echemi records, RDAP, and archived policies point to a China-centered trading operation behind a U.S.-listed brand, with the legal counterparty still unresolved. The report maps Reta-Peptide to Retalux, Peptaura batch tokens, lookalike domains, and direct-payment gaps.

38 pages7 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.06
94%
28
2
Retatrutide
$1.00
85%
90
3
Tirzepatideselected
$0.47
85%
39
4
Ipamorelin
$0.72
77%
17
5
PT-141
$0.60
72%
6
6
SS-31
$0.66
70%
6
7
Semaglutide
$0.50
70%
2
8
Melanotan II
$0.40
63%
5
9
Cagrilintide
$1.35
58%
4
10
BPC-157
$0.78
53%
21
11
Tesamorelin
$2.48
50%
19
12
MOTS-c
$0.57
40%
10
13
TB-500
$1.50
38%
13
14
CJC-1295
-
32%
9
15
NAD+
$0.01
30%
4
16
5-Amino-1MQ
$1.40
-
0
17
GLOW
$0.31
-
0
18
hCG
$0.00
-
0
19
HGH
$0.54
-
0
20
Kisspeptin
$0.99
-
0
21
KLOW
-
-
0
22
KPV
$0.75
-
0
23
LL-37
$1.52
-
0
25
SLU-PP-332
$2.40
-
0
27
Wolverine
$1.26
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%20 Jun 2025: 69%16 Jul 2025: 67%25 Jul 2025: 73%21 Aug 2025: 76%4 Sep 2025: 80%4 Sep 2025: 81%4 Sep 2025: 83%18 Sep 2025: 85%1 Oct 2025: 86%1 Oct 2025: 87%3 Oct 2025: 89%9 Oct 2025: 89%23 Oct 2025: 90%5 Nov 2025: 91%6 Nov 2025: 92%25 Nov 2025: 92%18 Dec 2025: 92%29 Dec 2025: 89%29 Dec 2025: 89%29 Dec 2025: 86%22 Jan 2026: 87%13 Feb 2026: 87%4 Mar 2026: 84%13 Mar 2026: 84%13 Mar 2026: 85%23 Apr 2026: 86%28 Apr 2026: 86%8 May 2026: 87%13 May 2026: 87%4 Jun 2026: 84%12 Jun 2026: 85%15 Jun 2026: 85%16 Jun 2026: 86%16 Jun 2026: 86%13 Jul 2026: 87%13 Jul 2026: 87%5 Nov 2026: 84%9 Nov 2026: 85%9 Nov 2026: 85%15 Nov 2026: current 85%69%92%85%Jun 25Nov 26
Showing Tirzepatide tests only
Peptide testing

Ordered Tirzepatide from Reta-Peptide? Mail in a sample (US only) and let us test it.

Test my supply
Reta-Peptide Tirzepatide test history
COA-backed lab tests
1-10 of 39

About Reta-Peptide test results from Finnrick

Reta-Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 15 peptides and 273 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Reta-Peptide peptides in this dataset are BPC-157 (21 tests), Cagrilintide (4 tests) and CJC-1295 (9 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests. It also includes 1 correction related to this vendor.

Corrections
2025-09-26
Customer update
Batch identifier provided after publishing. Test score updated from 7.3 to 9.3.
Peptide testing

Ordered Tirzepatide from Reta-Peptide? Mail in a sample (US only) and let us test it.

Test my supply